Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC), one of the most fatal malignancies in the world, is usually diagnosed in advanced stages due to late symptom manifestation with very limited therapeutic options, which leads to ineffective intervention and dismal prognosis. For a decade, tyrosine kinase inhibitors (TK...
Guardado en:
Autores principales: | Rui Xing, Jinping Gao, Qi Cui, Qian Wang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4df16459bfcb422d82a06d08fb6c79aa |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Identification of a Pyroptosis-Related Gene Signature for Predicting Overall Survival and Response to Immunotherapy in Hepatocellular Carcinoma
por: Susu Zheng, et al.
Publicado: (2021) -
Nanobubbles Containing sPD-1 and Ce6 Mediate Combination Immunotherapy and Suppress Hepatocellular Carcinoma in Mice
por: Tan Y, et al.
Publicado: (2021) -
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma
por: Petros Fessas, et al.
Publicado: (2021) -
Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies
por: Hui Tian, et al.
Publicado: (2021) -
Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors
por: Nicola Personeni, et al.
Publicado: (2021)